iCAD of Nashua, New Hampshire won FDA approval of the cervical applicator for its Xoft Axxent Electronic Brachytherapy System. The technology delivers high dose radiation directly to the target. The new applicator will allow clinicians to target tumors within the uterus, cervix, endometrium and vagina. Unlike radioactive isotopes, electronic brachytherapy can be turned on and off, allowing for more control and easier repositioning, hopefully reducing exposure of healthy tissue.
In addition to the applicator, parallel approval was given for upgrades to the Axxent controller to support the new applicator and provide additional features.
Here’s more about the Xoft Axxent device from the product page:
- The Axxent System mimics 192Ir in the treatment area, but greatly reduces the amount of radiation delivered to the rest of the body, providing greater sparing of healthy organs
- Axxent FlexiShield attenuates radiation exposure to the patient’s healthy tissue and allows treatment personnel to remain in the treatment room.
- Delivers the therapeutic dose directly to the tumor bed.
Product page: Axxent Electronic Brachytherapy System…
Press release: iCAD Announces FDA Clearance of Cervical Applicator for Xoft Electronic Brachytherapy System…
